JAZZ PHARMACEUTICALS PLC (JAZZ) Stock Price, Forecast & Analysis
USA - NASDAQ:JAZZ - IE00B4Q5ZN47 - Common Stock
JAZZ Key Statistics, Chart & Performance
The current stock price of JAZZ is 137.64 USD. In the past month the price decreased by -1.32%. In the past year, price increased by 24.62%.
JAZZ Latest News, Press Relases and Analysis
JAZZ Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 39.24 | 816.66B | ||
| JNJ | JOHNSON & JOHNSON | 18.2 | 454.86B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.56 | 255.48B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.83 | 239.64B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 12.81 | 219.77B | ||
| MRK | MERCK & CO. INC. | 9.87 | 214.76B | ||
| PFE | PFIZER INC | 7.27 | 140.15B | ||
| SNY | SANOFI-ADR | 11.52 | 123.27B | ||
| GSK | GSK PLC-SPON ADR | 7.73 | 94.25B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.02 | 93.77B | ||
| ZTS | ZOETIS INC | 23.17 | 63.86B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 48 | 42.45B |
Related stock screener links
About JAZZ
Company Profile
Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. The company is headquartered in Dublin, Dublin and currently employs 2,800 full-time employees. The company went IPO on 2012-01-18. The company is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. The company has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
Company Info
JAZZ PHARMACEUTICALS PLC
Fifth Floor, Waterloo Exchange, Waterloo Road, Dublin 4
DUBLIN DUBLIN D04 IE
CEO: Bruce C. Cozadd
Employees: 2800
Phone: 35316347800
JAZZ PHARMACEUTICALS PLC / JAZZ FAQ
Can you describe the business of JAZZ PHARMACEUTICALS PLC?
Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. The company is headquartered in Dublin, Dublin and currently employs 2,800 full-time employees. The company went IPO on 2012-01-18. The company is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. The company has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
What is the stock price of JAZZ PHARMACEUTICALS PLC today?
The current stock price of JAZZ is 137.64 USD. The price increased by 0.98% in the last trading session.
What is the dividend status of JAZZ PHARMACEUTICALS PLC?
JAZZ does not pay a dividend.
What is the ChartMill technical and fundamental rating of JAZZ stock?
JAZZ has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Can you provide the number of employees for JAZZ PHARMACEUTICALS PLC?
JAZZ PHARMACEUTICALS PLC (JAZZ) currently has 2800 employees.
What is the Short Interest ratio of JAZZ PHARMACEUTICALS PLC (JAZZ) stock?
The outstanding short interest for JAZZ PHARMACEUTICALS PLC (JAZZ) is 7.98% of its float.
JAZZ Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to JAZZ. When comparing the yearly performance of all stocks, JAZZ is one of the better performing stocks in the market, outperforming 81.04% of all stocks.
JAZZ Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to JAZZ. JAZZ has a medium profitability rating, but doesn't score so well on its financial health evaluation.
JAZZ Financial Highlights
Over the last trailing twelve months JAZZ reported a non-GAAP Earnings per Share(EPS) of 6.64. The EPS decreased by -62.78% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -3.7% | ||
| ROE | -10.92% | ||
| Debt/Equity | 1.17 |
JAZZ Forecast & Estimates
25 analysts have analysed JAZZ and the average price target is 190.69 USD. This implies a price increase of 38.54% is expected in the next year compared to the current price of 137.64.
For the next year, analysts expect an EPS growth of -74.4% and a revenue growth 4.37% for JAZZ